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Introduction 
 
Nanotechnology offers substantial potential to revolutionize the drug delivery system. In 
the last few decades, there has been tremendous progress in the development of therapeutic 
nanoparticles.1 Size of nanoparticles range from 1 to 100 nm and these dimensions allows 
the particles to interact with the biological systems in interesting ways.2 Several advantages 
of nanoparticles include drug targeting to specific sites, the ability to cross biological 
barriers, protection of the drug from degradation, and prolonged circulation times.3 In 
addition, nanoparticles can be used for various route of drug administration such as oral, 
ocular, and parenteral.4 These advantages of nanoparticles provide for promotion in drug 
bioavailability and reduction in toxicity.   
 
Flash Nanoprecipitation (FNP) is a technique used to construct drug-loaded polymeric 
nanoparticles. In the technique of FNP, hydrophobic molecules and polymer are dissolved 
in an organic solvent and rapidly mixed with the aqueous antisolvent. Upon rapid mixing 
of the organic solvent and antisolvent, a condition of high supersaturation is attained which 
leads to the nucleation and growth of particles. The block copolymer stabilized the surface 
of the particle and arrest particle growth, resulting in precipitation of specific size 
distribution of nanoparticles.5 Most importantly, FNP is an inexpensive and scalable 
process that can generate stable nanoparticles with high drug loading and encapsulation 
efficiency.6  
 
 
Figure 1. Schematic representation of the Flash Nanoprecipitation process in a Confined 
Impingement Jets mixer.7 
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In FNP, mixing of organic solvent and antisolvent occurs in a confined mixing chamber 
which can vary in geometry and size. In a Confined Impingement Jets (CIJ) mixer, the 
organic solute and stabilizing polymer are dissolved in the organic stream. The organic 
stream and the antisolvent stream collide each other at equal ratio of solvent to anti-solvent 
(Figure 1).7 Higher supersaturations levels are limited through the use of CIJ. The Multi-
Inlet Vortex Mixer (MIVM) design allows unequal ratio of solvent to anti-solvent mixing 
which overcomes the limitation of the CIJ (Figure 2).8 Moreover, the CIJ has a two-inlet 
design compared to the MIVM which has a four-inlet design that allows additional streams 
of MQ water and increase supersaturation in the rapid mixing process.9,10 The additional 
volume of water in the mixing process, decrease the solubility of the drug and result in 
higher precipitation of nanoparticles. Figure 2 shows the arrangement of the four inlet 
streams on the MIVM and an example stream composition for FNP. 
 
 
Figure 2. Schematic representation of the Flash Nanoprecipitation process in the Multi-
Inlet Vortex Mixer.8 
 
It is estimated that 40% of active ingredients developed in pharmaceutical industry are 
poorly water-soluble drugs.11 Oral drug delivery is the most convenient and preferred route 
of administration based on low cost-effectiveness and high patient compliance.12 
Administration of poorly-water soluble drugs provided the motivation for oral delivery 
through nanoparticle-based therapeutics.13 Hydrophobic small molecule drugs are difficult 
to absorb in the body due to poor water solubility and low dissolution rate in water. 
Formulation of a poorly water-soluble compound using a nanoparticle approach can 
enhance dissolution rate, drug solubility, and bioavailability.14 In comparison of 
nanoparticles to conventional crude suspension, nanoparticles can minimize variation in 
bioavailability of fed vs. fasted state.15 In addition, many poorly water-soluble molecules 
are not dose proportional. Nanoparticle formulations of these molecules can improve or 
implement dose proportionality.16 Moreover, drug nanoparticles have higher surface area 
and surface interaction than particulates greater than 1 micron. The increased surface area 
 3 
 
of nano-size particles can enhance dissolution rate and maximize the amount of drug 
absorbed at the duodenal–jejunal area of the gastrointestinal tract.17 However, the 
enormous increase in surface area can cause nanoparticles to aggregate or agglomerate into 
a more thermodynamic stable state. For that reason, addition of stabilizing polymer is 
needed to dampen or sensitize the surface energy of the nanoparticles through steric and/or 
ionic interaction.18 
 
In formulating nanoparticles for oral delivery of small molecule drug, a weakly 
hydrophobic Genentech drug named “G-1” is used for nanoparticle formulation. “G-1” has 
a log P of 6.18 and pKa of 4.3. The chemical structure of the drug has two notable functional 
groups: carboxylic acid and indazole. The carboxylic acid can be deprotonated with a base 
to generate carboxylate anion for nanoparticle formation. Various excipients such as 
Hydroxypropyl Methylcellulose Acetate Succinate (HPMCAS), Hydroxypropyl 
Methylcellulose E3 (HPMC E3), polyethylene glycol (PEG), polyvinyl alcohol (PVA), 
Vitamin E TPGS and polystyrene-b-poly(ethylene glycol) (PS-b-PEG) were tested as 
stabilizing polymer to encapsulate “G-1” into nanoparticles. Numerous nanoparticle 
formulations are investigated through the FNP process via CIJ and MIVM. These 
formulations include changes in drug concentration, percent of drug, percent of stabilizing 
polymer, type of stabilizing polymer, equivalents of base, pH of antisolvent, choice of 
organic solvent, volume of organic and antisolvents.  
 
The goal of this capstone project is to improve the oral bioavailability of a small molecule 
hydrophobic drug (“G-1”) by formation of nanoparticles through the FNP process. The 
objective is to formulate nanoparticles of different sizes suitable for oral delivery and 
process nanoparticles into dried powder form which can demonstrate re-dispersibility. 
HPMCAS is a widely used polymer for spray-dried dispersion and hot melt extrusion in 
the pharmaceutical industry.19,20 HPMCAS can enhance the solubility and increase 
bioavailability of poorly soluble active pharmaceutical ingredients. Genentech generated 
amorphous solid dispersion of “G-1” with HPMCAS by spray drying.21 The drug 
dissociates from the HPMCAS polymer in vivo and precipitate to form nanoparticle in situ. 
In this work, the usage of HPMCAS as a stabilizing polymer to encapsulate “G-1” into 
nanoparticles was investigated for comparison to Genentech’s spray-dried dispersion of 
“G-1” with HPMCAS. Formulation of different size nanoparticles can provide size-
dependent dissolution profile and better understanding in the pharmacokinetics of this 
drug. Nanoparticles in dry stable form are desirable for transportation and long-term 
storage. Cryoprotectants are added into the nanoparticle suspensions before lyophilization 
to stabilized against aggregation during freezing.22 Testing of various selection of 
cryoprotectant is vital for re-dispersion of dried powders into nanometer-sized particles 
when placed in water or an alternative water-based environment. It is critical that these 
dried powders are capable of re-dispersing into non-aggregated/non-agglomerated 
nanoparticulate dispersion for the development of solid dosage form.23 The re-dispersed 
nanoparticles will be screened for their end application criteria: size, polydispersity index 
(PDI), and stability. Formulations are optimized based on the re-dispersity of the 
nanoparticles. Samples of the final formulations are sent to Genentech for dissolution 
testing and pharmacokinetic studies. 
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Materials and Method 
 
Materials 
Affinisol HPMC-AS 126 G (>94% purity), Affinisol HPMC-AS 716 G (>94% purity), 
Affinisol HPMC-AS 912 G (>94% purity), and Methocel E3 Premium LV Hydroxypropyl 
Methylcellulose (HPMC E3) were purchased from Dow Chemicals. Tetrahydrofuran 
(HPLC grade, 99.9%), methanol (HPLC grade, 99.9% purity), dimethyl sulfoxide (HPLC 
grade, 99.9% purity), acetone (HPLC grade, 99.9% purity), Tween 80, Tween 20, and 
sodium hydroxide pellets were purchased from Fisher Chemicals. Phosphate buffered 
saline (10X) was purchased from Lonza. Hydrochloric acid and potassium chloride were 
purchased from EMD Millipore. Pluronic F-127 was purchased from BASF Corporation. 
Vitamin E-TPGS were purchased from Peboc. Hydroxypropyl-β-cyclodextrin were 
purchased from Acros Organics. Poly(vinyl alcohol), polyethylene glycol and mannitol 
(>98% purity) were purchased from Sigma Aldrich. Fasted-state simulated intestinal fluid 
(FaSSIF) and fedstate simulated intestinal fluid (FeSSIF) were purchased from 
Biorelevant.com. “G-1” was supplied by Genentech. Trehalose (>99% purity) was 
purchased from Fluka. Poly(styrene)1.6kDa-block-poly(ethylene glycol)5kDa were purchased 
from were purchased from Polymer Source Inc. DI (DI) water (18.2 MΩ·cm) was prepared 
by a NANOpure Diamond UV ultrapure water system (Barnstead International, Dubuque, 
IA).  
 
Solubility Profile of “G-1” and HPMCAS-126 
An excess of different organic solvent (methanol, tetrahydrofuran, dimethyl sulfoxide, and 
acetone) was added separately to glass vials containing 15.0 mg of “G-1”. Solutions of 
HPMCAS-126 in different organic solvent (methanol, tetrahydrofuran, dimethyl sulfoxide, 
and ethanol) at a concentration of 20 mg/mL were prepared. Visual observation on the 
solubility of “G-1” and HPMCAS-126 was conducted.  
 
Precipitation and Solubility Studies of “G-1” 
A solution of 1x PBS was prepared through a tenfold dilution with 10x PBS. “G-1” in 
different organic solvent (methanol, tetrahydrofuran, and dimethyl sulfoxide) at a 
concentration of 20 mg/mL were generated and were mixed with antisolvent (water or 
PBS) in a final volume of 1.5 mL at different percentages, ranging from 90 % of the organic 
solvent and 10 % of antisolvent to 10 % of the organic solvent and 90 % of the antisolvent. 
The mixed solvent with precipitation were centrifuged at 14800 rpm for 15 minutes. A 
sample was aliquot out of the supernatant of the solution. The sample was diluted up to 
1000-fold and analyzed by UV-vis spectrometry. 
 
Preparation of “G-1” Nanoparticles. 
“G-1” with HPMCAS 
A pellet of sodium hydroxide was added to methanol to prepare a stock solution at a 
concentration of 10 mg/mL through sonication. A stock solution of HPMCAS-126 in 
methanol at a concentration of 20 mg/mL with 0.50 and 0.75 equivalents of sodium 
hydroxide were prepared. A stock solution of “G-1”in methanol at a concentration of 20 
mg/mL were prepared. Attempts to generated “G-1” nanoparticles with HPMCAS were 
prepared via CIJ and MIVM. The organic stream consisted of “G-1”and HPMCAS-126 
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dissolved in 0.5 mL of methanol were prepared with the stock solutions. The rapid mixing 
of organic stream and antisolvent DI water streams was conducted via CIJ and MIVM. The 
mixture was subsequently dispersed in 9.0 mL (CIJ) or 6.0 mL (MIVM) of DI water which 
decrease the organic solvent to 10 vol%. 
 
“G-1” with various excipients (HPMC E3, F-127, PVA, Tween 80, and Vitamin E TPGS) 
“G-1” nanoparticles with various excipients to act as stabilizing polymers were prepared 
via MIVM. The antisolvent 10 mM HCl streams were prepared by dilution of 1M HCl with 
DI water. The three antisolvent stream consisted of 1.0 mL of 10 mM HCl or DI water 
were rapidly mixed with the organic stream which consisted of “G-1” (20 mg/mL) and 
stabilizing polymer (2 mg/mL) in 0.5 mL of methanol via MIVM. The mixture was 
dispersed into a quench bath of DI water (6.0 mL), resulting in a final organic concentration 
of 10 vol%.  
 
“G-1” with no stabilizing polymers 
“G-1” nanoparticles in suspension without stabilizing polymers were generated by FNP 
using the four-stream MIVM. Different concentration of “G-1”in methanol (20 mg/mL, 40 
mg/mL, 80 mg/mL, and 160 mg/mL) was prepared with different equivalents of sodium 
hydroxide (0.00 eq, 0.05 eq, 0.10 eq, 0.20 eq, and 0.40 eq) for the organic stream (1.0 mL) 
in the MIVM. Rapid mixing of the organic stream and the three antisolvent DI water stream 
(1.0 mL each) was conducted via MIVM. The suspension mixture was dispersed as 
previously described.  
 
“G-1” with PS-b-PEG 
PS-b-PEG “G-1” nanoparticles in suspension were generated by FNP using the four-stream 
MIVM. Different amount of % drug (25, 50, 75% and etc.) and % PS-b-PEG (75, 50, 25% 
and etc.) were dissolved in 0.5 mL of methanol (total mass concentration: 40 mg/mL or 20 
mg/mL). The rapid mixing of the organic stream (0.5 mL of methanol) and antisolvent 
stream (4.5 mL of DI water) resulted in a mixture with a final organic concentration of 10 
vol% which was dispersed into a 20 mL vial. 
 
“G-1” with increased drug loading (wt%) 
“G-1” nanoparticles (80 mg/mL of “G-1” with 0.05 eq of NaOH) in suspension were 
generated as previously described. The rapid mixing of the organic stream (4.0 mL of 
methanol) and antisolvent stream (12.0 mL of DI water) was conducted via MIVM. The 
mixture was dispersed into a quench bath of DI water (24.0 mL), resulting in a final 
organic concentration of 10 vol%. The nanoparticle suspension (40.0 mL) underwent 
filtration using a MicroKros® Module (MWCO: 100 kD) and removed water (32.0 mL) 
from solution, concentrating the nanoparticle suspension by 5-fold. 
 
Nanoparticle Characterization 
Nanoparticle size and PDI were assessed by dynamic light scattering using a Zetasizer 
Nano-ZS at 25 °C with a detection angle of 173° in triplicate. To avoid multiple light 
scattering, the samples were diluted 10-fold prior to DLS. The size is determined through 
a series of light scattering correlation function. The PDI is obtained through the Taylor 
 6 
 
series expansion of the correlation function from the Malvern Nanosizer data analysis 
software.  
 
Nanoparticle Lyophilization 
Nanoparticle suspensions were lyophilized into dry powders using a benchtop VirTis 
Advantage without and with cryoprotectants (i.e. PVA, PEG, Trehalose, Mannitol, F-127, 
and HPMC E3). 200 mg of cryoprotectant were added to 5 mL of nanoparticle solutions to 
afford NP:cryoprotectant weight ratios of 1:5. The mixture solution were flash frozen in a 
container of dry ice. The frozen samples were transferred to the freeze-dryer at -20 °C 
under vacuum to remove the water and organic solvents from the nanoparticles. After 24 
hours, dried powders were obtained and stored at -20 °C. Samples were re-disperse with 5 
mL of DI water for DLS analysis. 
 
“G-1” Solubility and Release Kinetics 
FeSSIF (Fed State Simulated Intestinal Fluid) and FaSSIF (Fasted State Simulated 
Intestinal Fluid) buffer consisted of different percentage of Tween 20 (0.5% and 1.5%) 
were prepared. An excess of “G-1” powder was added to FeSSIF and FaSSIF buffer, 
respectively, followed by a slow rotation on the Glas-Col rotator for 96 h to allow 
maximum saturation of the drug in solution. The solution was aliquot into Amicon and Pall 
filters to remove the undissolved drug from the solution. The solution was centrifuged at 
5000 rcf for 10 minutes. The supernatant of the solution was analyzed by UV-vis 
spectrometry. The concentration of “G-1” was calculated using a calibration curve with 
known standard solution. In the dissolution testing procedures, approximately 5.0 mg of 
“G-1” is added to 20.0 mL of FaSSIF with 1.5% Tween. Solution was aliquot into Pall 
filters and the supernatant of the solution was analyzed by UV-Vis spectrometry at 15-
minute and 30-minute timepoint. The concentration of “G-1” at each time point was 
calculated using a standard curve.  
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Results and Discussion 
 
Solubility Profile of “G-1” and HPMCAS 
In the FNP process, the drug and the stabilizing polymer are dissolved in the organic 
solvent and rapidly mixed with the antisolvent to form nanoparticles in suspension. Thus, 
several common organic solvents (e.g., methanol, THF, DMSO and acetone) were screened 
as candidates for the FNP process. Solubility of “G-1” and HPMCAS in the organic 
solvents were qualitative measured by visual representations. The solubility of “G-1” was 
tested in methanol, THF, DMSO, and acetone. “G-1” is found to be soluble in all four 
solvents. The solubility of HPMCAS was tested in acetone, ethanol, methanol, and THF. 
HMPCAS is found to be soluble in all solvents except ethanol (Table 1). Methanol, THF, 
DMSO, and acetone were selected as the organic solvent for the FNP process as “G-1” and 
HPMCAS were both soluble in those solvents.   
 
Table 1. Solubility profiling of “G-1” and HPMCAS in different solvents. 
 Methanol THF DMSO Acetone Ethanol 
“G-1” Soluble Soluble Soluble Soluble N/A 
HPMCAS Soluble Soluble  Soluble Soluble Insoluble 
 
“G-1” Detection by UV-Vis 
Ultraviolet–visible spectroscopy (UV-Vis) can be used to detect the presence of “G-1” and 
determine the concentration of “G-1” in an organic solvent. UV-Vis was used to analyzed 
“G-1” in methanol, THF, DMSO and acetone, respectively. Analysis of “G-1” in methanol 
(50 μg/mL) by UV-Vis gave corresponding absorption peaks at the wavelength of 255 nm 
and 305 nm (Figure 3). Absorption spectrum of the blank methanol solution (blue line) 
and “G-1” methanol solution (orange line) is shown in Figure 3. “G-1” in methanol 
absorbed most strongly at 255 nm and 305 nm wavelength, creating two maxima in the 
absorption spectrum. In addition, “G-1” can be detected in THF and DMSO by UV-Vis as 
absorption spectrum can be generated from the drug in either solvents. However, UV-Vis 
cannot be used for the detection of “G-1” in acetone due to the overlap absorption peak of 
blank acetone and the absorption peak of the drug at 305 nm.  
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Figure 3. “G-1” dissolved in methanol and its corresponding absorption peak at 305 nm 
shown from the UV-VIS. 
 
Precipitation and Solubility Studies of “G-1” 
High “G-1” supersaturation must be achieved for formation of nanoparticles when the 
organic stream and antisolvent stream collide in FNP. For that reason, precipitation and 
solubility studies of “G-1” in methanol, THF, and DMSO were performed to investigate 
potential organic solvent for the FNP process. “G-1” in different organic solvents 
(methanol, THF, and DMSO) were separately mixed with antisolvent deionized (DI) water 
at different percentage to generate three series of mixtures (Series A, Series B, and Series 
C) and were observed for precipitation (Table 2). Each series of mixture were prepared 
with different organic solvents: Series A (methanol), Series B (THF), and Series C 
(DMSO). In series B, precipitation of the drug occurs at 40% THF and 60% DI water. In 
series A and C, precipitation of the drug occurs at 60% methanol or DMSO and 40% DI 
water. Calibration curves were constructed in methanol by preparing a series of 
concentrations of the drug (1, 5, 10, 25, 50, 75 μg/mL). Solubility curves of “G-1” were 
generated from four final mixed solvents (Figure 4). Solubility curve of “G-1” in four final 
mixed solvents (methanol with DI water, methanol with PBS, THF with DI water, and 
DMSO with DI water) are shown in Figure 4. The replacement of DI water with PBS was 
expected to decrease the solubility of “G-1” in methanol. However, “G-1” in methanol with 
PBS had a higher solubility curve compare to “G-1” in methanol with DI water. Similarly, 
the solubility curve of “G-1” in THF with DI water was higher than the solubility curve of 
“G-1” in methanol with DI water. The solubility curve of “G-1” in DMSO with DI water 
displayed a similar trend to the solubility curve of “G-1” in methanol with DI water. 
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Although, supernatant of the solution and the precipitation of “G-1” at 20% DMSO could 
not be separated through centrifugation. Most importantly, solubility of “G-1” is lowest at 
20% methanol. In other words, vast amount of “G-1” precipitate at 20% methanol and high 
supersaturation is desired for the FNP process. Thus, methanol was selected for the organic 
stream in the FNP process due to the low solubility of “G-1” in the final mixed solvent.  
 
Table 2. Precipitation studies of “G-1” in different solvents. P = Precipitation and NP = 
No Precipitation. 
Organic 
Solvent % 
Antisolvent % Series A 
Methanol:Water 
Series B 
THF:Water 
Series C 
DMSO:Water 
100 % 0 % NP NP NP 
90 % 10 % NP NP NP 
80 % 20 % NP NP NP 
70 % 30 % NP NP NP 
60 % 40 % P NP P 
50 % 50 % P NP P 
40 % 60 % P P P 
30 % 70 % P P P 
20 % 80 % P P P 
10 % 90 % P P P 
0 % 100 % P P P 
 
 
Figure 4. Solubility of “G-1” in mixtures of organic solvents to antisolvent in different 
percentages (Methanol:Water, Methanol:PBS, DMSO:Water, and THF:Water).  
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“G-1” Nanoparticles 
HPMCAS is a cellulosic derivative polymer with acetyl and succinyl substitutions along 
its backbone (Figure 5). In addition, HPMCAS is a polymer that can provide stable 
amorphous solids dispersions with poorly soluble drugs. Hypothetically, the succinate 
groups on HPMCAS can be deprotonated with a base which allows the anionic succinate 
group to act as the surface stabilizing polymer to encapsulate “G-1” into nanoparticles. 
Various formulations consisted of different percentage of drug and HPMCAS-126 in 0.50 
and 0.75 equivalents of sodium hydroxide was conducted through via CIJ and MIVM 
(Table 3). The formulations that underwent the FNP process in an attempt to form “G-1” 
nanoparticles with HPMCAS are listed in Table 3. Initial formulations were conducted via 
CIJ and later formulations were conducted via MIVM, in order to increase precipitation of 
“G-1” nanoparticles by introducing higher volume of DI water during the FNP process to 
decrease the solubility of “G-1” in methanol. Several variables of the formulations were 
modified such as increasing equivalents of sodium hydroxide and changing the percentage 
of the drug and HPMCAS-126. attempts to form “G-1” nanoparticles with HPMCAS. For 
all formulations tested in Table 3, no formulations were successful in forming “G-1” 
nanoparticles with HPMCAS-126. It is hypothesized that “G-1” form electrostatically 
stabilized nanoparticles which have an anionic surface that repels the anionic succinate 
groups of HPMCAS, preventing HPMCAS to act as a stabilizing polymer with the drug to 
form nanoparticles.  
 
 
Figure 5. Chemical structure of Hydroxypropyl Methylcellulose Acetate Succinate. 
 
To investigate whether “G-1” and its free acid form can participate in nanoparticle 
formation, a series of formulation consisted of “G-1” and various excipients (HPMC E3, 
F-127, PVA, Tween 80, and Vitamin E TPGS) dissolved in methanol (1.0 mL) were rapidly 
mixed with 10 mM HCl or DI water through the FNP process via MIVM (Table 4). The 
series of formulations were observed for nanoparticle formation and aggregation in the 
quench bath. The list of different formulations tested through the FNP process in an attempt 
to form “G-1” nanoparticles with a stabilizing polymer are shown in Table 4. Through 
visual observation, no aggregation was found in the formulations with DI water as the 
antisolvent. In addition, aggregation was found in all formulations with 10 mM HCl as the 
antisolvent except when F-127 was used as stabilizing polymer. In particular, three 
formulations resulted in forming well defined nanoparticles with “G-1” (Figure 6). Particle 
size distribution of the three successful nanoparticle formulation (PVA in DI water, vitamin 
E TPGS in DI water, and F-127 in 10 mM HCl) are shown in Figure 6. The size of the 
nanoparticles produced from these formulations were less than 200 nm with narrow size 
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distribution (PDI > 0.25). “G-1” nanoparticles can be formulated with specific stabilizing 
polymer and antisolvents.  
 
Table 3. Formulations to prepare "G-1" nanoparticles with HPMCAS.a 
Type of 
Mixer 
Total mass 
concentration 
Sodium 
Hydroxide 
Equivalents to 
HPMCAS 
% Drug % HPMCAS-
126 
 
Nanoparticle 
formation with 
HPMCAS-126 
CIJ 20 mg/mL 0.50 eq 100% 0% No 
CIJ 20 mg/mL 0.50 eq 75% 25% No 
CIJ 20 mg/mL 0.50 eq 50% 50% No 
MIVM 20 mg/mL 0.50 eq 100% 0% No 
MIVM 20 mg/mL 0.50 eq 90% 10% No 
MIVM 20 mg/mL 0.50 eq 50% 50% No 
MIVM 20 mg/mL 0.75 eq 90% 10% No 
MIVM 20 mg/mL 0.75 eq 50% 50% No 
a Methanol (0.5 mL) was used as the organic stream.  
 
Table 4. Formulations consisted of “G-1” with different stabilizing polymers in 
combination with 10 mM HCl or DI water as antisolvent.a  
“G-1” 
Concentration 
Stabilizing 
Polymer 
Concentration 
Stabilizing 
Polymers 
Antisolvent NP 
Formation 
(Size >200 nm) 
(PDI >0.25) 
20 mg/mL 2 mg/mL HPMC E3 10 mM HCl No 
20 mg/mL 2 mg/mL F-127 10 mM HCl Yes 
20 mg/mL 2 mg/mL PVA 10 mM HCl No 
20 mg/mL 2 mg/mL Tween 80 10 mM HCl No 
20 mg/mL 2 mg/mL Vitamin E TPGS 10 mM HCl No 
20 mg/mL 2 mg/mL HPMC E3 DI water No 
20 mg/mL 2 mg/mL F-127 DI water No 
20 mg/mL 2 mg/mL PVA DI water Yes 
20 mg/mL 2 mg/mL Tween 80 DI water No 
20 mg/mL 2 mg/mL Vitamin E TPGS DI water Yes 
a Methanol (1.0 mL) was used as the organic stream. 
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Figure 6. Particle size distribution of “G-1” nanoparticles with different stabilizing 
polymer and antisolvents. 
 
Table 5. Formulations consisted of “G-1” with different equivalents of sodium 
hydroxide.a 
“G-1” 
Concentration 
Sodium 
Hydroxide 
Equivalents 
(eq) 
Antisolvent NP 
Formation 
Size Size 
Distribution 
(PDI) 
20 mg/mL 0.05 DI water Yes 80 0.23 
20 mg/mL 0.10 DI water Yes 60 0.23 
20 mg/mL 0.20 DI water Yes 50 0.28 
20 mg/mL 0.40 DI water Yes 40 0.26 
a Methanol (1.0 mL) was used as the organic stream. 
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Figure 7. Particle size distribution of “G-1” nanoparticles formed under different 
equivalents (0.00 eq, 0.05 eq, 0.10 eq, 0.20 eq and 0.40 eq) of NaOH. 
 
 
Figure 8. Particle size distribution of “G-1” nanoparticles formed with 160 mg/mL of 
“G-1” and 0.20 eq of NaOH. 
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Table 6. Formulations consisted of “G-1” with various grade of HPMCAS in different 
equivalents of sodium hydroxide.a 
“G-1” 
Concentration 
Sodium 
Hydroxide 
Equivalents 
(eq) 
Stabilizing 
Polymer 
Concentration 
Stabilizing 
Polymers 
Antisolvent NP 
Formation 
 
40 mg/mL 0.00 20 mg/mL HPMCAS-
126 
DI water No 
40 mg/mL 0.50 20 mg/mL HPMCAS-
126 
DI water No 
40 mg/mL 0.75 20 mg/mL HPMCAS-
126 
DI water No 
40 mg/mL 0.00 20 mg/mL HPMCAS-
712 
DI water No 
40 mg/mL 0.50 20 mg/mL HPMCAS-
712 
DI water No 
40 mg/mL 0.75 20 mg/mL HPMCAS-
712 
DI water No 
40 mg/mL 0.00 20 mg/mL HPMCAS-
912 
DI water No 
40 mg/mL 0.50 20 mg/mL HPMCAS-
912 
DI water No 
40 mg/mL 0.75 20 mg/mL HPMCAS-
912 
DI water No 
a Methanol (1.0 mL) was used as the organic stream. 
 
“G-1” (20 mg/mL) with different equivalents of sodium hydroxide (0.00 eq, 0.05 eq, 0.10 
eq, 0.20 eq, and 0.40 eq) generate nanoparticles through FNP via MIVM (Table 5). The 
list of different formulations tested through the FNP process in an attempt to form “G-1” 
nanoparticles with different equivalents of sodium hydroxide are tabulated in Table 5.  
Particle size distribution of “G-1” nanoparticles formulated with different equivalents of 
sodium hydroxide were measured by DLS (Figure 7). Figure 7 shows an inverse 
correlation between the size of “G-1” nanoparticles and the equivalents of sodium 
hydroxide. The size of “G-1” nanoparticles decrease as higher equivalents of sodium 
hydroxide was used in the formulation for the FNP process. The size of nanoparticles can 
be controlled from ~40 to ~80 nm based on the equivalent amount of sodium hydroxide 
used in the formulation process. The formulation was optimized for further downstream 
processing, higher concentrations of “G-1” was tested for nanoparticle formation. “G-1” at 
concentrations of 40 mg/mL, 80 mg/mL, and 160 mg/mL formed nanoparticles. Particle 
size distribution of “G-1” nanoparticles formulated with 160 mg/mL of “G-1” and 0.20 eq 
of NaOH was measured by DLS (Figure 8). “G-1” at a concentration of 160 mg/mL were 
able to form nanoparticles with sizes around ~100 nm, and slightly narrow size distribution 
(PDI 0.31). In addition, various grade of HPMCAS (HPMCAS-126, HPMCAS-712, and 
HPMCAS-912) in different equivalents of sodium hydroxide (0.00 eq, 0.50 eq, 0.75 eq) 
with “G-1” (40 mg/mL) was formulated for nanoparticle formation (Table 6). “G-1” did 
 15 
 
not form nanoparticle with the different grades of HPMCAS and aggregation was visually 
observed for all formulations tested. In summary, HPMCAS failed to act as a stabilizing 
polymer with “G-1” to form nanoparticles. 
 
Freeze-drying of “G-1” Nanoparticles and Redispersion 
Lyophilization is a process widely used in pharmaceuticals to dry and improve the stability 
of pharmaceutical products.24 “G-1” with 0.05 equivalents and 0.20 equivalents of sodium 
hydroxide generated nanoparticles that were desirable for lyophilization. Formulations for 
these nanoparticles were pursued for further testing with various stabilizing polymer and 
cryoprotectants for freeze-drying. “G-1” with 0.05 equivalents of sodium hydroxide 
nanoparticles and “G-1” with 0.20 equivalents of sodium hydroxide nanoparticles with 
different stabilizing polymers were lyophilized without any cryoprotectants (Table 7). 
Formulations with different equivalents of sodium hydroxide and stabilizing polymers 
conducted through the FNP process via MIVM are listed in Table 7. The dry powder form 
of “G-1” were re-dispersed with DI water and analyzed through DLS. The “G-1” powder 
failed to re-dispersed back to nanoscale and form aggregation upon re-dispersion with DI 
water.  
 
The process of freeze-drying can induce mechanical stress that could destabilize colloidal 
suspension of nanoparticles and cause nanoparticles to aggregate. For that reason, 
cryoprotectants are added to the nanoparticle suspension before freezing to protect the 
nanoparticles from freezing stress and preserve re-dispersibility of the nanoparticles.25 
HPMC E3 is a water-soluble HPMC polymer and serves as a cryoprotectant.26 Three 
formulations were tested with HPMC E3 to determine if HPMC E3 is an effective 
cryoprotectant for “G-1” nanoparticles. “G-1” with different equivalents of sodium 
hydroxide (0.00 eq, 0.05 eq, and 0.20 eq) nanoparticles with HPMC E3 were lyophilized 
(Table 8). The formulations tested with HPMC E3 as cryoprotectant were conducted 
through the FNP process via MIVM are listed in Table 8. The dry powder form of “G-1” 
were re-dispersed with DI water and analyzed through DLS. In conclusion, HPMC E3 was 
not an effective cryoprotectant and failed to form powder that can re-disperse back to 
nanoscale. 
 
“G-1” nanoparticles with 0.05 equivalents of sodium hydroxide and “G-1” nanoparticles 
with 0.20 equivalents of sodium hydroxide were lyophilized into dried powder form. Seven 
excipients (PVA, PEG, trehalose, Mannitol, F-127, cyclodextrin, and propylvinylpyridone) 
were tested to determine which excipient is the most effective cryoprotectant for re-
dispersion of freeze-dried “G-1” powder. The lyophilized powder of “G-1” nanoparticles 
with good redispersity retains similar size and size distribution as nanoparticles before 
lyophilization. Freeze dried powder of “G-1” with 0.05 equivalents of sodium hydroxide 
re-dispersed into nanoparticles in DI water when PEG or trehalose is selected as the 
cryoprotectant for lyophilization (Figure 9). Particle size distribution of the re-dispersed 
“G-1” with 0.05 equivalents of sodium hydroxide nanoparticles with trehalose and “G-1” 
with 0.05 equivalents of sodium hydroxide nanoparticles with PEG are shown in Figure 
9. These nanoparticles redispersed back to nanoscale when PEG or trehalose is used as a 
cryoprotectant. Trehalose was the most effective cryoprotectant in redispersion of “G-1” 
nanoparticles formulated with 0.05 equivalents of sodium hydroxide as size and size 
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distribution were similar to nanoparticles before lyophilization. In addition, freeze dried 
powder of “G-1” with 0.20 equivalents of sodium hydroxide re-dispersed into 
nanoparticles in DI water when PEG is selected as the cryoprotectant for lyophilization 
(Figure 10). The particle size distribution of re-dispersed “G-1” with 0.20 equivalents of 
sodium hydroxide nanoparticles with PEG are shown in Figure 10. The dried powder did 
not re-disperse back to nanoscale when trehalose was used as a cryoprotectant.  
 
Table 7. Formulations consisted of “G-1” with and without stabilizing polymers in 
different sodium hydroxide equivalents.a 
“G-1” 
Concentration 
Sodium 
Hydroxide 
Equivalents 
(eq) 
Stabilizing 
Polymer 
Concentration 
Stabilizing 
Polymers 
Antisolvent Dispersion 
of NP 
80 mg/mL 0.05 N/A N/A DI water No 
80 mg/mL 0.20 N/A N/A DI water No 
80 mg/mL 0.05 2 mg/mL PVA DI water No 
80 mg/mL 0.20 2 mg/mL PVA DI water No 
80 mg/mL 0.05 2 mg/mL Vitamin E 
TPGS 
DI water No 
80 mg/mL 0.20 2 mg/mL Vitamin E 
TPGS 
DI water No 
a Methanol (1 mL) was used as the organic stream. 
 
Table 8. Formulations consisted of “G-1” with HPMC E3 in different sodium hydroxide 
equivalents.a 
“G-1” 
Concentration 
Sodium 
Hydroxide 
Equivalents 
(eq) 
Stabilizing 
Polymer 
Concentration 
Stabilizing 
Polymers 
Antisolvent Dispersion 
of NP 
20 mg/mL 0.00 20 mg/mL HPMC E3 DI water No 
20 mg/mL 0.05 20 mg/mL HPMC E3 DI water No 
20 mg/mL 0.20 20 mg/mL HPMC E3 DI water No 
a Methanol (1 mL) was used as the organic stream. 
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Figure 9. Particle size distribution of “G-1” with 0.05 equivalents of sodium hydroxide 
nanoparticles before and after lyophilization with selected cryoprotectants (PEG and 
trehalose).  
 
 
Figure 10. Particle size distribution of “G-1” with 0.20 equivalents of sodium hydroxide 
nanoparticles before and after lyophilization with PEG as the selected cryoprotectant. 
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Trehalose was the most effective cryoprotectant for lyophilization of “G-1” nanoparticles. 
The average size of the re-disperse “G-1” nanoparticles increased by 10 nm with similar 
PDI. Different mass ratios of trehalose to nanoparticles (5:1, 4:1, 3:1, 2:1, and 1:1) was 
tested to determine the minimum amount of trehalose required to behave as a 
cryoprotectant. The re-dispersed “G-1” nanoparticles with different mass equivalents of 
trehalose (5:1, 4:1, and 3:1) was analyzed through DLS (Figure 11). Particle size 
distribution of different mass equivalents of trehalose to “G-1” nanoparticles (5:1, 4:1, and 
3:1) are shown in Figure 11. High amount of aggregation was observed for formulations 
with 2:1 and 1:1 ratio, and thus particle size distribution could not be analyzed by DLS. 
The formulation (80 mg/mL of “G-1” with 0.05 equivalents of NaOH in MeOH) with 5 
mass equivalents of trehalose was repeated and the nanosuspension was lyophilized. The 
dried powder was sent to Genentech for pharmacokinetics studies. The results from 
Genentech conclude that the “G-1” nanoparticles with trehalose have faster dissolution rate 
than the nanoparticles formed in vivo from Genentech's spray dried dispersion. 
 
 
Figure 11. Particle size distribution of “G-1” nanoparticles with different amount of 
trehalose.  
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“G-1” is insoluble in water (log P = 6.18). For oral delivery, rapid dissolution rate 
(complete dissolution of drug in less than one hour) of the drug is desirable for high 
bioavailability. A rapid dissolution rate of the drug results in high solubility of the drug in 
a short amount of time. In this objective, solubility of “G-1” in biorelevant media was 
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“G-1” in solution compare to “G-1” nanoparticles. The release experiments were 
performed on the free “G-1” powder to compare with the release kinetics of “G-1” 
nanoparticles. In dissolution testing procedures, sink condition is described as a dissolution 
system that has volume of solvent which is five to ten times greater than the volume of 
solvent present in a saturated solution.27 In other words, a “sink” is required to prevent 
saturation in a dissolution assay. In order to mimic the oral administration of “G-1”, FeSSIF 
and FaSSIF were selected as biorelevant media for in vitro dissolution tests which stimulate 
the physiological condition in the gastrointestinal tract. FeSSIF and FaSSIF contains 
biological lipids such as sodium taurocholate and lecithin which can act as a lipid sink for 
the drug. However, the undissolved nanoparticles cannot be separated from the large lipid 
globules through centrifugation or filtration due to similar size of the nanoparticles and 
lipid globules, thus an alternative media is necessary for the dissolution testing. 
 
Tween 20 can be used to mimic biological lipids which can facilitate separation from the 
undissolved nanoparticle. Most importantly, Tween 20 can act as a hydrophobic sink to 
increase the solubility of “G-1” in FaSSIF and FeSSIF media.28 In preparation of the 
modified biorelevant media, Tween 20 (0.5% and 1.5%) were added to FeSSIF and FaSSIF 
buffers in substitution of the SIF powder which contains the biological lipids, sodium 
taurocholate and lecithin. Four different dissolution media (FaSSIF with 0.5% Tween 20, 
FaSSIF with 1.5% Tween 20, FeSSIF with 0.5% Tween 20, and FeSSIF 1.5% Tween 20) 
were prepared and free “G-1” powder was added to each media to determine the maximum 
saturation of the drug in solution and its sink conditions. The pH and concentration of “G-
1” in each dissolution media was measured by pH indicator and UV-Vis, respectively 
(Table 9). Among the four different dissolution media, “G-1” in FaSSIF with 1.5% Tween 
20 had the highest maximum saturation solubility (2504 μg/mL). FaSSIF with 1.5% Tween 
20 was selected for dissolution testing of “G-1” with the sink condition at 250 μg/mL, ten 
times below saturation limit.  
 
Methods of separating undissolved “G-1” from dissolved “G-1” were investigated for the 
dissolution test. Undissolved and dissolved “G-1” was separated by Amicon filter (made 
of regenerated cellulose) and the concentration of “G-1” were measured. High levels of 
adsorption to the filter membrane were observed. The concentration of filtered “G-1” was 
substantially lower than the concentration of “G-1” before filtration as shown in Table 9. 
Standard curve of “G-1” before filtration and after Pall filtration (made of modified 
polyethersulfone) was generated (Figure 12). Minor adsorption to the filter membrane 
were quantitatively observed. The concentration of “G-1” did not change dramatically   
There are minimal differences between the two different standard curves of “G-1”: before 
filtration (blue line) and after Pall filtration (orange line). In order to achieve the sink 
condition of the dissolution test (250 μg/mL), 5.0 mg of “G-1” is added to 20.0 mL of 
FaSSIF with 1.5% Tween. Dissolution testing of “G-1” in FaSSIF with 1.5% Tween 20 
was performed and the concentration of “G-1” was measured by UV-Vis (Figure 13). In 
addition, the maximum saturation solubility for the dissolution test (250 μg/mL) was 
measured by UV-Vis and the absorbance value of the maximum saturation solubility is 
1.52 au. In Figure 13, about >90% of the free “G-1” powder had dissolved in solution 
within the first timepoint (15 minutes). Due to rapid dissolution of the free “G-1” powder, 
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dissolution test for “G-1” nanoparticles were not tested as it would be difficult to 
differentiate the differences in release kinetics between the free powder drug and the drug 
nanoparticle.  
 
Table 9. Measurements of pH, maximum saturation solubility, and maximum saturation 
solubility in FaSSIF and FeSSIF solutions with different amounts of Tween 20 (0.5% or 
1.5%) 
Dissolution 
Media 
pH “G-1” Concentration 
(maximum saturation 
solubility) 
“G-1” Concentration 
after Amicon filter 
(maximum saturation 
solubility) 
FaSSIF in 0.5% 
Tween 20  
6.36 644 μg/mL 473 μg/mL 
FaSSIF in 1.5% 
Tween 20  
6.17 2504 μg/mL 792 μg/mL 
FeSSIF in 0.5% 
Tween 20  
5.00 292 μg/mL 147 μg/mL 
FeSSIF in 1.5% 
Tween 20 
5.02 1226 μg/mL 412 μg/mL 
 
 
Figure 12. Standard curve of “G-1” before filtration and after Pall filtration. 
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Figure 13. Release kinetic of “G-1” in FaSSIF with 1.5% Tween 20. 
 
Increase Nanoparticle Size Formulation 
Various formulations were investigated to increase the size of “G-1” nanoparticles for 
comparison with Genentech’s spray-dried dispersion of “G-1” with HPMCAS which 
precipitate and formed 200 to 800 nm particles in vivo. Formulation of different size 
nanoparticles can provide more in-depth knowledge about the dissolution behavior and oral 
absorption of “G-1”. Particle size is often related to the solubility of the drug. The decrease 
in solubility of the drug result in larger particles due to the particles having less interaction 
with the solvent.29 Hydrophobicity of the drug is increased when “G-1” is in its free acid 
form which allow the polymer to stabilize the drug nanoparticle. By decreasing the 
solubility and increasing the hydrophobicity of “G-1”, larger size nanoparticles can be 
generated. Concentration of “G-1” in four different solutions was measured by UV-Vis: 
HCl, KCl, HCl with KCl, and DI water (Table 10). Among the four solutions, “G-1” had 
the lowest solubility in 10 mM HCl. “G-1” is insoluble in 10 mM HCl as concentration of 
“G-1” in 10 mM HCl was below detection limit. 10 mM HCl was selected as the antisolvent 
to completely protonate drug and reduce surface charge in the formation of nanoparticles. 
 
Table 10. Solubility of “G-1” in HCl, KCl, HCl with KCl, and DI water. 
Solution “G-1” Concentration 
10 mM HCl Below detection limit 
150 mM KCl 4 μg/mL 
10 mM HCl and 150 mM KCl 2 μg/mL 
DI water 37 μg/mL 
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Formulation to generate ~200 to 300 nm particles from “G-1” were desired. The DLS 
analysis of formulations to generate ~200 to 300 nm “G-1” nanoparticle is tabulated in 
Table 11. For all formulations shown in Table 11, THF was selected for the organic stream 
and 10 mM HCl was selected for the antisolvent stream in the FNP process. In addition, 
all the formulations are conducted via MIVM and the nanoparticle suspension were 
measured by DLS. Polystyrene-b-poly(ethylene glycol) (PS-b-PEG) is an amphiphilic 
diblock copolymer which can stabilize hydrophobic drug nanoparticles formed by flash 
nanoprecipitation (FNP).30 THF was selected for the organic stream in the FNP process 
because PS-b-PEG is soluble in THF and not soluble in methanol. PS-b-PEG polymer were 
able to form “G-1” nanoparticles, with sizes ranging from ~100 to ~500 nm, and narrow 
size distribution, (PDI 0.07−0.22).  
 
In entry #1 to #3, different percentage of drug (25.0, 50.0, and 75.0%) and PS-b-PEG (75.0, 
50.0, and 25.0%) were formulated to generate PS-b-PEG nanoparticles. In entry #4, 
formulation consisted of “G-1” without PS-b-PEG was conducted to investigate whether 
PS-b-PEG is necessary for the formation of nanoparticles. “G-1” nanoparticles did not form 
without PS-b-PEG and aggregations were visually observed. In entry #5, formulation 
without the quench bath was conducted to observe whether the quench bath affect the 
formation of nanoparticles. Particle size increased from 220 nm to 500 nm when quench 
bath is removed in the formulation. The water in the quench bath plays a role in the 
assembly of PS-b-PEG nanoparticles. Formulation consisting 75% antisolvent and 25% 
organic solvent in mixer, quenched to 10% organic solvent were switched to 90% 
antisolvent and 10% organic solvent in the mixer, without quench bath. These formulations 
were modified to observe the effects of higher volume of antisolvent in the mixing chamber 
and to retain 10% vol of organic solvent in the final solution. Overall, nanoparticle size 
decrease in entry #6, #7, and #8 compare to entry #1, #2, and #3, respectively.  
 
Size of nanoparticles can be controlled in FNP by two process variables: the percent core 
(hydrophobic drug) of the formulation and the total mass concentration of solids 
(hydrophobic drug and stabilizer) in the solvent stream.31 In entry #9 to #11, formulations 
with increasing % drug (75.0%, 87.5% and 100.0%) were conducted to determine its size 
range. The size of nanoparticles increased as % drug increase in the formulations. To 
increase the size of nanoparticles and concentration of drug in the nanoparticle suspension, 
the total mass concentration in the formulation were switched from 20 mg/mL to 40 mg/mL 
in entry #12 and #13. 80.0% drug loading and 85.0% drug loading was selected for testing 
because the desired size of nanoparticles is between 75.0% drug and 87.5% drug (167 nm 
and 488 nm). The 85.0% drug loading generated nanoparticles that had a small increase in 
size compare to 80.0% drug loading.  Entry #12 generated PS-b-PEG nanoparticles, with 
size at 165 nm and narrow size distribution (PDI 0.07) The stability of the 80.0% drug 
loading nanoparticles was measured by DLS (Table 12). Size increase of “G-1” 
nanoparticles were observed over different timepoints (0, 30, 60 minutes). The particle size 
started at 185 nm and the size of the nanoparticle increase to 230 nm at 30-minute timepoint 
which further increase to 320 nm at 60-minute timepoint. The size increase in the stability 
study can explained by the phenomenon referred to as Ostwald ripening. Ostwald ripening 
results from uncontrollable precipitation which leads to particle-size growth following 
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stabilization.32 The 80% formulation was repeated to test for re-dispersity with various 
cryoprotectant.  
 
Table 11. Formulations conducted to generate ~200 to 300 nm “G-1” nanoparticles. a,b  
Entry Total Mass 
Concentration 
% Drug % PS-b-PEG Quench 
Bath 
Size 
(nm) 
PDI 
#1 a 20 mg/mL 25.0% 75.0% Yes 
(6.0 mL) 
335 0.22 
#2 a 20 mg/mL 50.0% 50.0% Yes 
(6.0 mL) 
220 0.10 
#3 a 20 mg/mL 75.0% 25.0% Yes 
(6.0 mL) 
215 0.08 
#4 a 20 mg/mL 100.0% 0.0% Yes 
(6.0 mL) 
N/A N/A 
#5 a 20 mg/mL 50.0% 50.0% No 505 0.07 
#6 b 20 mg/mL 25.0% 75.0% No 205 0.15 
#7 b 20 mg/mL 50.0% 50.0% No 130 0.07 
#8 b 20 mg/mL 75.0% 25.0% No 160 0.07 
#9 b 20 mg/mL 75.0% 25.0% No 170 0.07 
#10 b 20 mg/mL 87.5% 12.5% No 490 0.21 
#11 b 20 mg/mL 100.0% 0.0% No 785 0.14 
#12 b 40 mg/mL 80.0% 20.0% No 165 0.07 
#13 b 40 mg/mL 85.0% 15.0% No 225 0.09 
 
a For entry #1-5, THF (1.0 mL) was used for the organic stream and HCl (3.0 mL, 10 
mM) as an antisolvent.  
b For entry #6-13, THF (0.5 mL) was used for the organic stream and HCl (4.5 mL, 10 
mM) as an antisolvent. 
 
Table 12. Stability study of PS-b-PEG “G-1” nanoparticles (Formulation: 80% Drug + 
20% PS-b-PEG in 0.5 mL THF (TMC = 40 mg/ml) and 4.5 mL of 10 mM HCl water). 
Timepoint Size (nm) PDI 
0 min 185 0.05 
30 min 230 0.09 
60 min 320 0.20 
 
The nanoparticle suspension (Formulation: 80% Drug + 20% PS-b-PEG in 0.5 mL THF 
(TMC = 40 mg/ml) and 4.5 mL of 10 mM HCl water) was lyophilized without and with 20 
mg/mL of cryoprotectants (PEG, cyclodextrin, and trehalose) at the 30-minute timepoint 
(Table 13). The lyophilized nanoparticles were tested for re-dispersity and analyzed 
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through DLS. The size and PDI of the re-disperse nanoparticles with various cryoprotectant 
are listed in Table 13. Cyclodextrin was the most effective cryoprotectant for 
lyophilization of PS-b-PEG “G-1” nanoparticles. The PS-b-PEG “G-1” nanoparticles re-
dispersed, with size at 325 nm, and narrow size distribution, (PDI 0.26). However, 
substantial amount of aggregation was found in suspension. The formulation was repeated 
and lyophilized with 40 mg/mL of cyclodextrin to improve re-dispersion. No aggregation 
was found in the nanoparticle suspension. Moreover, the stability of the re-dispersed PS-
b-PEG “G-1” nanoparticles was measured by the DLS (Table 14). The size and size 
distribution of the re-dispersed nanoparticles are listed in Table 14.  The re-dispersed 
nanoparticles were stable as size and PDI remain nearly unchanged. 
 
Table 13. Re-dispersity test of PS-b-PEG “G-1” nanoparticles with different 
cryoprotectants (Formulation: 80% Drug + 20% PS-b-PEG in 0.5 mL THF (TMC = 40 
mg/ml) and 4.5 mL of 10 mM HCl water). 
Cryoprotectants Size (nm) PDI 
No Cryoprotectant N/A N/A 
PEG 460 0.53 
Cyclodextrin 325 0.26 
Trehalose N/A N/A 
 
Table 14. Stability study of re-dispersed PS-b-PEG “G-1” nanoparticles with 
cyclodextrin (Formulation: 80% Drug + 20% PS-b-PEG in 0.5 mL THF (TMC = 40 
mg/ml) and 4.5 mL of 10 mM HCl water). 
Timepoint Size (nm) PDI 
0 min 365 0.22 
15 min 350 0.21 
30 min 350 0.22 
60 min 360 0.20 
 
Increase Drug Loading (Wt%) Formulation 
Nanoparticle formulations with higher drug loading is desired. At a higher drug loading, 
less non active excipients are used to produce the same quantity of active pharmaceutical 
ingredient (API) in the nanoparticle formulation and a lower number of nanoparticles need 
to be manufactured to deliver the same dose of API.33 The objective is to generate “G-1” 
nanoparticles with highest drug loading possible and good redispersity. In the original 
formulation (80 mg/mL of “G-1” in 0.05 eq of NaOH with concentration of trehalose at 40 
mg/mL), the drug loading (wt%) of the lyophilized “G-1” nanoparticle is 16.7%. In 
addition, decreasing the amount of trehalose result in poorer redispersion of nanoparticles. 
It is hypothesized that a critical concentration of trehalose is required to act as a 
cryoprotectant. The removal of water can concentrate nanosuspension and thus allows 
cryoprotectant to interact with the nanoparticles in suspension more effectively. By 
concentrating nanoparticles before lyophilization, less cryoprotectant compared to drug 
mass is needed. 
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In order to increase drug weight % in the lyophilized nanoparticles, methods to increase 
nanoparticle concentration was investigated. Tangential Flow Filtration (TFF) was used to 
increase the concentration of nanoparticles by removing the water in the nanoparticle 
suspension through filtration. “G-1” nanoparticles were formulated through the FNP 
process via MIVM. The nanosuspension was concentrated by 5-fold (8 mg/mL into 40 
mg/mL) through TFF. The concentration of “G-1” nanoparticles suspension before 
filtration and after filtration was measured by UV-Vis. The concentration of “G-1” 
nanoparticles suspension before filtration is 8 mg/mL. The concentration of “G-1” 
nanoparticles suspension after filtration is 35 mg/mL. The concentrated nanosuspension 
was tested against different concentration of trehalose in the lyophilization process. The 
dried powder was re-dispersed into nanoparticles and analyzed through DLS (Table 15). 
Particle size distribution of the re-dispersed nanoparticles are tabulated in Table 15. 
Concentrated “G-1” nanoparticles with 80 mg/mL of trehalose (Increased Concentration 
#2) re-disperse better than all other formulations. The size and the size distribution of the 
re-disperse nanoparticles were the closest to the original formulation. The drug loading in 
“Increased Concentration #2” formulation (30.5 wt% drug) is nearly double, compare to 
the drug loading in the original formulation (16.7 wt% drug).  
 
Table 15. Re-dispersity test of concentrated “G-1” nanoparticles (80 mg/mL of “G-1” in 
0.05 eq of NaOH) with different concentration of cryoprotectant (trehalose) 
Formulation Nanoparticle 
Concentration 
(mg/mL) 
Trehalose 
Concentration 
(mg/mL) 
% Drug 
Loading 
in Dried 
Powder 
Size 
(nm) 
PDI 
Original 8 40 16.7% 88 0.21 
Increased 
Concentration #1 
35 40 46.6% 151 0.30 
Increased 
Concentration #2 
35 60 36.8% 185 0.41 
Increased 
Concentration #3 
35 80 30.5% 126 0.25 
Increased 
Concentration #4 
35 120 22.5% 137 0.31 
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Conclusion 
 
The oral bioavailability of “G-1” was improved through the formation of nanoparticles 
through FNP. “G-1” formed ~80 nm particles which are self-stabilized without additional 
use of steric copolymers. Nanoparticles can be formed with concentration of “G-1” as high 
as 160 mg/mL. Lyophilization of “G-1” nanosuspensions with trehalose as cryoprotectant, 
result in good redispersion of “G-1” nanoparticles. The dried powder of the final 
formulations was sent to Genentech. The nanoparticles with trehalose show faster 
dissolution rate than the nanoparticles formed in vivo from Genentech's spray dried 
dispersion. Due to the rapid dissolution rate of free “G-1” powder, the differences in the 
release kinetics of the free powder and the nanoparticles could not be discerned. Series of 
formulations were conducted through the FNP process to generate ~300 nm “G-1” 
nanoparticles. Nanoparticles with higher drug loading was achieved. Specifically, drug 
loading of the original formulation was increased from 16.7% to 30.5%. The dried powder 
of the final formulations (“G-1” nanoparticles with trehalose, ~300 nm “G-1” particles, and 
30.5 wt% drug “G-1” nanoparticles) was sent to Genentech for better understanding in the 
dissolution behavior of “G-1”, contributing to the knowledge of nanomedicine and 
pharmaceutical sciences at Genentech. 
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